On 7 May 2024, Galderma announced that its nemolizumab, for the treatment of prurigo nodularis and for moderate to severe atopic dermatitis has been accepted for review in Australia, Singapore, Switzerland and the UK under the Access Consortium Framework, a collaboration between regulatory authorities of those four countries plus Canada. Galderma expects to receive an approval decision from the Consortium in 2025.
Regulatory filings for nemolizumab were accepted by the FDA and EMA in February 2024.